These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33934279)

  • 21. Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
    Desborough M; Hadjinicolaou AV; Chaimani A; Trivella M; Vyas P; Doree C; Hopewell S; Stanworth SJ; Estcourt LJ
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012055. PubMed ID: 27797129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Avatrombopag for adults with early versus chronic immune thrombocytopenia.
    Virk ZM; Leaf RK; Kuter DJ; Goodarzi K; Connell NT; Connors JM; Al-Samkari H
    Am J Hematol; 2024 Feb; 99(2):155-162. PubMed ID: 38063420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison.
    Cooper KL; Fitzgerald P; Dillingham K; Helme K; Akehurst R
    Int J Technol Assess Health Care; 2012 Jul; 28(3):249-58. PubMed ID: 22980701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia.
    Lozano ML; Godeau B; Grainger J; Matzdorff A; Rodeghiero F; Hippenmeyer J; Kuter DJ
    Expert Rev Hematol; 2020 Dec; 13(12):1319-1332. PubMed ID: 33249935
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative Efficacy and Safety of Thrombopoietin Receptor Agonists in Adults With Thrombocytopenia: A Systematic Review and Network Meta-analysis of Randomized Controlled Trial.
    Deng J; Hu H; Huang F; Huang C; Huang Q; Wang L; Wu A; Yang J; Qin D; Zou W; Wu J
    Front Pharmacol; 2021; 12():704093. PubMed ID: 34393785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.
    Jurczak W; Chojnowski K; Mayer J; Krawczyk K; Jamieson BD; Tian W; Allen LF
    Br J Haematol; 2018 Nov; 183(3):479-490. PubMed ID: 30191972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Avatrombopag for the treatment of immune thrombocytopenia.
    Długosz-Danecka M; Zdziarska J; Jurczak W
    Expert Rev Clin Immunol; 2019 Apr; 15(4):327-339. PubMed ID: 30799645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China.
    Wang Z; Zhang A; Xu Z; Wang N; Zhang J; Meng J; Dong S; Ma J; Hu Y; Ouyang J; Chen Z; An Q; Cheng X; Wu R
    Br J Haematol; 2024 May; 204(5):1958-1965. PubMed ID: 38362793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD; Herrington JD
    Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
    Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
    Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension.
    Al-Samkari H; Nagalla S
    Platelets; 2022 Feb; 33(2):257-264. PubMed ID: 33586606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.
    Lee D; Thornton P; Hirst A; Kutikova L; Deuson R; Brereton N
    Appl Health Econ Health Policy; 2013 Oct; 11(5):457-69. PubMed ID: 23857462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
    Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
    Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of treatments for persistent/chronic immune thrombocytopenia: a systematic review and network meta-analysis.
    Arai Y; Matsui H; Jo T; Kondo T; Takaori-Kondo A
    Platelets; 2019; 30(8):946-956. PubMed ID: 30507320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of romiplostim in children and adolescents with Immune thrombocytopenia: A systematic review.
    de Oliveira FL; Sequeira FS; Garanito MP
    Hematol Transfus Cell Ther; 2023; 45(1):83-89. PubMed ID: 36273985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.
    Boyers D; Jia X; Jenkinson D; Mowatt G
    Pharmacoeconomics; 2012 Jun; 30(6):483-95. PubMed ID: 22480381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
    Gilreath J; Lo M; Bubalo J
    Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia.
    Kuter DJ; Tarantino MD; Lawrence T
    Blood Rev; 2021 Sep; 49():100811. PubMed ID: 33781612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.
    Tarantino MD; Despotovic J; Roy J; Grainger J; Cooper N; Beam D; Raj A; Maschan A; Kim J; Eisen M
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28630. PubMed ID: 32902132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.